Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 37,500 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 37,500 shares of the business’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00. Following the transaction, the director owned 1,182,504 shares in the company, valued at $77,134,735.92. This represents a 3.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Down 3.2%

ESTA traded down $2.10 during midday trading on Thursday, reaching $64.51. The company’s stock had a trading volume of 839,456 shares, compared to its average volume of 508,999. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -37.07 and a beta of 1.08. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. Establishment Labs Holdings Inc. has a 1 year low of $28.67 and a 1 year high of $83.31. The stock’s 50-day moving average is $67.07 and its 200-day moving average is $63.96.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.19) earnings per share. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on ESTA. Canaccord Genuity Group upped their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Stephens upped their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. BTIG Research upped their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Finally, Citigroup dropped their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs in the fourth quarter worth approximately $47,000. Quarry LP bought a new position in shares of Establishment Labs in the third quarter worth approximately $34,000. State of Wyoming bought a new position in shares of Establishment Labs in the third quarter worth approximately $71,000. MV Capital Management Inc. bought a new position in shares of Establishment Labs in the fourth quarter worth approximately $146,000. Finally, Osaic Holdings Inc. lifted its stake in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.